This preliminary experience suggests that the risk of liver abscess among patients with prior biliary intervention may be lower following radioembolization than chemoembolization, which could potentially expand treatment options in this high-risk population.

CapTemY90 is feasible and safe for grade 2 NETs. Toxicities were additive. Oncologic outcomes suggest synergy.

No abstract

progressive disease in 2 (7.4%) (7 not determined). Liver function tests showed a significant reduction of mean serum albumin after SIRT (from 3.7 ± 0.53 g/dL [baseline] to 3.3 ± 0.64 g/dL [week 4, P<.001] and 3.0 ± 0.70 g/dL [week 12, P<.001]), and a significant increase in mean ALP values (from 218.0 ± 174.47 IU/L [baseline] to 244.9 ± 132.49 IU/L [week 8, P ¼ .008] and 313.9 ± 144.73 IU/L [week 12, P ¼ .002]). Mean ALT, AST, and total bilirubin were mostly within normal range during the 12-week follow-up. Most frequent SIRT-related adverse events included fatigue (26 patients), abdominal pain (20), nausea (12), weight loss (11), and abdominal disturbances (9). Most complications were grade 1-2; only 3 patients had grade 3 (abdominal distension and ascites, and abdominal pain and fatigue) or grade 4 (AST and ALT elevation) toxicities. Median survival from diagnosis was 20.8 mo. Age, sex, extrahepatic disease, and ECOG performance status were not significant predictors of survival. Conclusions: Y-90 SIRT meaningfully prolonged survival of heavily pretreated patients with liver metastases from pancreatic adenocarcinoma. Complications and liver toxicity remained acceptable and were rarely severe (grade 3).